Advanced Proteome Therapeutics Inc. has developed a proprietary approach for streamlining the production and targeted delivery of anti-cancer drugs to cancerous tumors. The benefit of targeted therapies, such as Advanced Proteome’s approach, is their ability to home in on cancer cells (while sparing healthy cells) thereby avoiding the nasty side effects of traditional chemotherapeutics.
The proprietary process we are implementing is versatile and exploits universal features of antibodies, thus simplifying and standardizing, as well as accelerating the process of creating new antibody-drug conjugates that are expected to be easier to produce and to exhibit greater potency, higher specificity and lower toxicity than current therapies.
Because of the benefits of our innovative approach over traditional approaches, we expect to profoundly impact the markets for anti-cancer therapeutics.